The molecular characterization of Tel action discloses a novel ERα pathway (i.e., IGF1‐R/AKT/FOXA1) influencing the control of ERα levels and BC cell proliferation and finally suggests Tel repurposing as a new approach for the treatment of ERα‐expressing BCs. This evidence concerns the gene ESR1 and breast cancer.